<VariationArchive RecordType="classified" VariationID="237937" VariationName="NM_000546.5(TP53):c.-202_*1207del" VariationType="Deletion" Accession="VCV000237937" Version="1" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2023-10-15" DateCreated="2016-07-01" MostRecentSubmission="2016-07-01">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="242581" VariationID="237937">
      <GeneList>
        <Gene Symbol="WRAP53" FullName="WD repeat containing antisense to TP53" GeneID="55135" HGNC_ID="HGNC:25522" Source="calculated" RelationshipType="genes overlapped by variant">
          <Location>
            <CytogeneticLocation>17p13.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="17" Accession="NC_000017.11" start="7686071" stop="7703502" display_start="7686071" display_stop="7703502" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="17" Accession="NC_000017.10" start="7589388" stop="7606819" display_start="7589388" display_stop="7606819" Strand="+" />
          </Location>
          <OMIM>612661</OMIM>
        </Gene>
        <Gene Symbol="LOC126862483" FullName="BRD4-independent group 4 enhancer GRCh37_chr17:7589699-7590898" GeneID="126862483" Source="calculated" RelationshipType="genes overlapped by variant">
          <Location>
            <CytogeneticLocation>17p13.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="17" Accession="NC_000017.11" start="7686360" stop="7687580" display_start="7686360" display_stop="7687580" Strand="+" />
          </Location>
        </Gene>
        <Gene Symbol="LOC130060171" FullName="ATAC-STARR-seq lymphoblastoid silent region 8136" GeneID="130060171" Source="calculated" RelationshipType="genes overlapped by variant">
          <Location>
            <CytogeneticLocation>17p13.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="17" Accession="NC_000017.11" start="7685851" stop="7685910" display_start="7685851" display_stop="7685910" Strand="+" />
          </Location>
        </Gene>
        <Gene Symbol="LOC130060172" FullName="ATAC-STARR-seq lymphoblastoid active region 11641" GeneID="130060172" Source="calculated" RelationshipType="genes overlapped by variant">
          <Location>
            <CytogeneticLocation>17p13.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="17" Accession="NC_000017.11" start="7686211" stop="7686340" display_start="7686211" display_stop="7686340" Strand="+" />
          </Location>
        </Gene>
        <Gene Symbol="TP53" FullName="tumor protein p53" GeneID="7157" HGNC_ID="HGNC:11998" Source="submitted" RelationshipType="genes overlapped by variant">
          <Location>
            <CytogeneticLocation>17p13.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="17" Accession="NC_000017.11" start="7668421" stop="7687490" display_start="7668421" display_stop="7687490" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="17" Accession="NC_000017.10" start="7571719" stop="7590867" display_start="7571719" display_stop="7590867" Strand="-" />
          </Location>
          <OMIM>191170</OMIM>
          <Haploinsufficiency last_evaluated="2021-11-10" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=TP53">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2021-11-10" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=TP53">No evidence available</Triplosensitivity>
          <Property>gene_acmg_incidental_2013</Property>
          <Property>gene_acmg_incidental_2016</Property>
          <Property>gene_acmg_incidental_2021</Property>
          <Property>gene_acmg_incidental_2022</Property>
        </Gene>
      </GeneList>
      <Name>NM_000546.5(TP53):c.-202_*1207del</Name>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>17p13.1</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="17" Accession="NC_000017.11" innerStart="7668402" innerStop="7687550" display_start="7668402" display_stop="7687550" variantLength="19149" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="17" Accession="NC_000017.10" innerStart="7571720" innerStop="7590868" display_start="7571720" display_stop="7590868" variantLength="19149" />
      </Location>
      <HGVSlist>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_321t1" sequenceAccession="LRG_321t1" change="c.-202-?_*1207+?del">
            <Expression>LRG_321t1:c.-202-?_*1207+?del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000017.11" sequenceAccession="NC_000017" sequenceVersion="11" change="g.(?_7668402)_(7687550_?)del" Assembly="GRCh38">
            <Expression>NC_000017.11:g.(?_7668402)_(7687550_?)del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000017.10" sequenceAccession="NC_000017" sequenceVersion="10" change="g.(?_7571720)_(7590868_?)del" Assembly="GRCh37">
            <Expression>NC_000017.10:g.(?_7571720)_(7590868_?)del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000546.5(TP53):c.-202_*1207del AND Li-Fraumeni syndrome" Accession="RCV000231533" Version="1">
        <ClassifiedConditionList TraitSetID="2589">
          <ClassifiedCondition DB="MedGen" ID="C0085390">Li-Fraumeni syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2016-04-01" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2016-04-01" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2016-07-01" MostRecentSubmission="2016-07-01">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <ConditionList>
          <TraitSet ID="2589" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="10539" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Li-Fraumeni syndrome</ElementValue>
                <XRef ID="MONDO:0018875" DB="MONDO" />
                <XRef Type="Phenotypic series" ID="PS151623" DB="OMIM" />
                <XRef ID="428850001" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Sarcoma family syndrome of Li and Fraumeni</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">LFS</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Li-Fraumeni syndrome (LFS) is a cancer predisposition syndrome associated with high risks for a diverse spectrum of childhood- and adult-onset malignancies. The lifetime risk of cancer in individuals with LFS is =70% for men and =90% for women. Five cancer types account for the majority of LFS tumors: adrenocortical carcinomas, breast cancer, central nervous system tumors, osteosarcomas, and soft-tissue sarcomas. LFS is associated with an increased risk of several additional cancers including leukemia, lymphoma, gastrointestinal cancers, cancers of head and neck, kidney, larynx, lung, skin (e.g., melanoma), ovary, pancreas, prostate, testis, and thyroid. Individuals with LFS are at increased risk for cancer in childhood and young adulthood; survivors are at increased risk for multiple primary cancers.</Attribute>
                <XRef ID="NBK1311" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="6902" />
                <XRef ID="6902" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301488</ID>
                <ID Source="BookShelf">NBK1311</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACS, 2007">
                <ID Source="PubMed">17392385</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2014">
                <ID Source="PubMed">24493721</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Breast and Gynecologic Cancers">
                <ID Source="PubMed">26389210</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2019">
                <URL>https://www.nice.org.uk/guidance/cg164</URL>
                <CitationText>UK NICE Clinical Guideline CG164, Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer, 2019</CitationText>
              </Citation>
              <XRef ID="524" DB="Orphanet" />
              <XRef ID="C0085390" DB="MedGen" />
              <XRef ID="MONDO:0018875" DB="MONDO" />
              <XRef Type="Phenotypic series" ID="PS151623" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="540393" SubmissionDate="2017-03-14" DateLastUpdated="2016-07-01" DateCreated="2016-07-01">
        <ClinVarSubmissionID localKey="464018|MedGen:C0085390" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000285169" DateUpdated="2016-07-01" DateCreated="2016-07-01" Type="SCV" Version="3" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2016-04-01">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment Type="public">A gross deletion of the genomic region encompassing the full coding sequence of the TP53 gene has been identified. The boundaries of this event are unknown as the deletion extends beyond the assayed region for this gene and therefore may encompass additional genes. A similar deletion encompassing the full coding sequence of the TP53 gene has been reported in the literature in a 66 year old female with breast cancer at 46 and leiomyosarcoma at 49 (PMID: 23172776). Additionally, a study evaluating eight probands with deletion events involving the TP53 gene suggests that full-length deletions of the entire TP53 gene have a milder cancer-predisposition phenotype than partial deletions of TP53 (PMID: 21056402). This variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="TP53" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000017.10:g.(?_7571720)_(7590868_?)del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0085390" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>2016June</SubmissionName>
          <SubmissionName>2017March_Invitae</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="540393" TraitType="Disease" MappingType="XRef" MappingValue="C0085390" MappingRef="MedGen">
        <MedGen CUI="C0085390" Name="Li-Fraumeni syndrome" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

